Alcidion Group Ltd (ASX: ALC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alcidion Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alcidion Group Ltd (ASX: ALC)
Latest News
Broker Notes
Why this growing ASX tech share could have 45% upside
Broker Notes
Bell Potter says this small-cap ASX share could rise 50%
Healthcare Shares
This ASX healthcare stock could be set to rise 50%
Broker Notes
Two ASX penny stocks Bell Potter thinks are worth watching in 2026
Technology Shares
This ASX technology company's shares are surging more than 20% on a new contract win
Earnings Results
Up 94% in a year, why is this ASX healthcare stock rocketing again today?
Healthcare Shares
Guess which ASX healthcare stock is rocketing 25% on big UK news
Healthcare Shares
2 ASX healthcare shares outperforming on big news
Healthcare Shares
Guess which ASX healthcare stock just rocketed 46% on major news!
Healthcare Shares
Why is the Alcidion share price crashing 27% to a 52-week low?
Broker Notes
400% organic growth in 3 years: The ASX small-cap Cyan is pumped about
Opinions
An unloved ASX stock I'm considering buying with $5,000 in August
Frequently Asked Questions
-
No, Alcidion does not pay dividends at this time.
-
Alcidion listed on the ASX on 24 June 2011.
ALC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alcidion Group Ltd
Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.
The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.
Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems. Other products include Smartpage and Patientrack software.
Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.
ALC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 07 Oct 2026 | $0.11 | $0.00 | 0.00% | 179,483 | $0.11 | $0.11 | $0.10 |
| 06 Oct 2026 | $0.10 | $0.00 | 0.00% | 1,189,226 | $0.10 | $0.11 | $0.10 |
| 05 Oct 2026 | $0.10 | $0.00 | 0.00% | 277,548 | $0.10 | $0.11 | $0.10 |
| 02 Oct 2026 | $0.10 | $0.00 | 0.00% | 317,762 | $0.10 | $0.11 | $0.10 |
| 01 Oct 2026 | $0.11 | $-0.01 | -9.09% | 1,961,489 | $0.11 | $0.11 | $0.10 |
| 30 Sep 2026 | $0.11 | $0.01 | 9.52% | 2,150,057 | $0.11 | $0.11 | $0.10 |
| 29 Sep 2026 | $0.11 | $0.00 | 0.00% | 29,548 | $0.10 | $0.11 | $0.10 |
| 28 Sep 2026 | $0.11 | $0.00 | 0.00% | 562,235 | $0.11 | $0.11 | $0.10 |
| 25 Sep 2026 | $0.11 | $0.00 | 0.00% | 219,668 | $0.10 | $0.11 | $0.10 |
| 24 Sep 2026 | $0.10 | $0.00 | 0.00% | 133,057 | $0.10 | $0.11 | $0.10 |
| 23 Sep 2026 | $0.10 | $0.00 | 0.00% | 113,234 | $0.10 | $0.11 | $0.10 |
| 22 Sep 2026 | $0.10 | $0.00 | 0.00% | 144,413 | $0.10 | $0.11 | $0.10 |
| 21 Sep 2026 | $0.10 | $0.00 | 0.00% | 556,553 | $0.10 | $0.11 | $0.10 |
| 18 Sep 2026 | $0.10 | $0.00 | 0.00% | 322,521 | $0.10 | $0.10 | $0.10 |
| 17 Sep 2026 | $0.10 | $0.00 | 0.00% | 469,166 | $0.11 | $0.11 | $0.10 |
| 16 Sep 2026 | $0.10 | $0.00 | 0.00% | 93,421 | $0.11 | $0.11 | $0.10 |
| 15 Sep 2026 | $0.10 | $0.00 | 0.00% | 1,090,958 | $0.10 | $0.10 | $0.10 |
| 14 Sep 2026 | $0.10 | $0.00 | 0.00% | 436,647 | $0.10 | $0.10 | $0.10 |
| 11 Sep 2026 | $0.11 | $0.00 | 0.00% | 550,083 | $0.10 | $0.11 | $0.10 |
| 10 Sep 2026 | $0.11 | $0.00 | 0.00% | 664,389 | $0.10 | $0.11 | $0.10 |
| 09 Sep 2026 | $0.10 | $0.00 | 0.00% | 89,073 | $0.10 | $0.10 | $0.10 |
| 08 Sep 2026 | $0.10 | $0.00 | 0.00% | 90,347 | $0.10 | $0.11 | $0.10 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 26 Aug 2026 | Andrew Way | Buy | 107,526 | $9,999 |
On-market trade.
|
| 26 Aug 2026 | Andrew Way | Buy | 107,526 | $9,999 |
On-market trade.
|
| 24 Aug 2026 | Andrew Way | Buy | 107,526 | $9,999 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Rebecca Jayne Wilson | Non-Executive DirectorNon-Executive Chairman | Jul 2017 |
Ms Wilson is an experienced company director with private, ASX listed and not-for-profit organisations. In her previous career, she held global leadership roles in marketing communication, investor relations, and corporate affairs. She has deep expertise in ESG, complex stakeholder communication, issues, crisis and risk management, transactions, and investor relations. She worked with multinational and growth companies in technology, healthcare, retail, and professional services sectors. Rebecca is experienced in leading companies during important commercial activation phases working with CEOs as both an advisor and non-executive director to develop and execute effective business strategy that supports accelerated and sustained growth. Rebecca is currently the Non-Executive Chair of AI-enabled technology company Clever Culture Systems Limited, and a Non-Executive Director of Hansen Technologies and Vitura Health Limited. She is a Non-Executive Director of NFP, The Tomisich Foundation and Veski. She is the chair of the Board.
|
| Mr William (Bill) Smart | Non-Executive Director | Oct 2024 |
Mr Smart is a digital health leader with over 30 years of experience leading transformational changes in organizations. Will has a track record of driving politically sensitive and operationally critical initiatives, enhancing organizational performance. Based in the United Kingdom, Will is currently Vice Chair of Aneurin Bevan University Health Board, Chair of the British Computer Society Faculty of Health and Care and was previously the CIO for Health and Social Care for England. In that role, Will provided advice to the Secretary of State for Health and Social Care and developed and delivered national strategies on information, technology and informatics. He has held executive roles in several NHS Trusts including as the Digital NED for Great Western Hospitals NHS FT, Group Chief Information Officer, Royal Free London NHS Foundation Trust. Will previously served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of their European built Electronic Patient Record (EPR) solution into Ireland and the UK.
|
| Ms Katrina (Kate) Elizabeth Doyle (Quirke) | Chief Executive OfficerExecutive DirectorManaging Director | Jul 2018 |
Ms Quirke has 25+ years of health sector experience and has been involved in procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia. Her background includes leading management roles at healthcare software firms where she has driven strategic product direction, global sales and operations. She believes technology can enable the transformation of healthcare delivery. Kate is currently a Non-Executive Director of ANDHealth.
|
| Mr Daniel Sharp | Non-Executive Director | Sep 2021 |
Mr Sharp has over 25 years of senior executive experience in investment banking and corporate finance. He was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Danny headed the corporate finance division at two leading independent Investment Banking/Stockbroking firms. Danny has managed the IPOs, capital raising and corporate advisory activities for many successful ASX listed companies in the healthcare, technologies and general industrials sectors. He is closely connected to networks of institutional, family office and net worth investors both in Australia and overseas. Danny is currently a Non-Executive Director of Botanix Pharmaceuticals and a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation.
|
| Professor Andrew Way | Non-Executive Director | Apr 2025 |
Prof. Way commenced his career as a nurse in the UK National Health Service (NHS) and after a range of clinical positions, moved first into nursing leadership and then into general management. Andrew has held several senior executive roles hospitals in both the UK NHS and Australia. He has been a Chief Executive for nearly 25 years, recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through major clinical and non-clinical digital transformations. Awarded an AM for his services in support of clinical research and leadership, he continues to advocate for integration of clinical research and clinical practice. Andrew is currently Board Chair of Latrobe Regional Health, Board Chair of HealthShare Victoria, a Director of Australian College of Health Service Management (ACHSM) and a Director of Melbourne Primary Care Network (MPCN). He continues to hold other health related advisory roles.
|
| Mr Michael Sapountzis | Company Secretary | Mar 2019 |
-
|
| Matthew Gepp | CFO |
-
|
|
| Michael Sapountzis | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 185,232,839 | 13.79% |
| Mr Malcolm Pradhan | 106,416,160 | 7.92% |
| Mr Raymond Howard Blight | 66,964,657 | 4.98% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient> | 49,523,333 | 3.69% |
| Mr Paul John Van Dyk | 41,191,171 | 3.07% |
| Citicorp Nominees Pty Limited | 40,869,955 | 3.04% |
| Mr Dean Anthony Mackenzie | 25,843,400 | 1.92% |
| Rewmicman Pty Ltd <Smallman Family A/C> | 25,232,039 | 1.88% |
| Mrs Katrina Elizabeth Doyle | 22,793,199 | 1.70% |
| MNMD Pty Ltd <Quirke Super Fund A/C> | 20,668,086 | 1.54% |
| Caledonia Nominees Pty Ltd <Caledonia A/C> | 19,976,377 | 1.49% |
| UBS Nominees Pty Ltd | 18,659,561 | 1.39% |
| Mast Financial Pty Ltd <A To Z Investment A/C> | 12,500,000 | 0.93% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 10,865,922 | 0.81% |
| Merrill Lynch (Australia) Nominees Pty Limited | 10,092,199 | 0.75% |
| Aylward Master Pty Ltd <Aylward Family Master A/C> | 10,000,000 | 0.74% |
| Gliocas Investments Pty Ltd <Gliocas Growth Fund A/C> | 9,380,393 | 0.70% |
| Sandhurst Trustees Ltd <Cyan C3G Fund A/C> | 8,553,043 | 0.64% |
| Emerald Shares Pty Limited <Emerald Unit A/C> | 7,150,000 | 0.53% |
| Mr Vivek Ramakrishnan and Miss Nisha Srinivasan | 7,021,913 | 0.52% |